Repurposing Ospemifene for Potentiating an Antigen-Specific Immune Response

od Kao, Chiao-Jung, Wurz, Gregory T., Lin, Yi-Chen, Vang, Daniel P., Phong, Brian, DeGregorio, Michael W.
izdano v Menopause (2017)

Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model

od Wurz, Gregory T, Gutierrez, Audrey M, Greenberg, Brittany E, Vang, Daniel P, Griffey, Stephen M, Kao, Chiao-Jung, Wolf, Michael, DeGregorio, Michael W
Izdano 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

od Vang, Daniel P., Wurz, Gregory T., Griffey, Stephen M., Kao, Chiao-Jung, Gutierrez, Audrey M., Hanson, Gregory K., Wolf, Michael, DeGregorio, Michael W.
Izdano 2013

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

od McCoach, Caroline E., Yu, Aiming, Gandara, David R., Riess, Jonathan W., Vang, Daniel P., Li, Tiahong, Lara, Primo N., Gubens, Matthew, Lara, Frances, Mack, Philip C., Beckett, Laurel A., Kelly, Karen
izdano v JCO Precis Oncol (2021)

Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions

od Floc’h, Nicolas, Martin, Matthew J., Riess, Jonathan W., Orme, Jonathan P., Staniszewska, Anna D., Menard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J, Ward, Richard A., Finlay, M. Raymond V., McKerrecher, Darren, Cheng, Mingshan, Vang, Daniel P, Tsai, Rebekah A., Keck, James G., Gandara, David R., Mack, Philip C., Cross, Darren, AE
izdano v Mol Cancer Ther (2018)